Skip to main content
IV zoledronic acid (ZA) does not prevent future knee replacement (TKR) in symptomatic knee OA without severe joint spa

Dr. John Cush RheumNow

2 years 3 months ago
IV zoledronic acid (ZA) does not prevent future knee replacement (TKR) in symptomatic knee OA without severe joint space narrowing (JSN). In 222 Knee OA pts, after 7 yrs F/U, ZA had more TKR (39% vs 30%; HR 4.2' 1.2-14.7) https://t.co/2cGeqz2Rwu https://t.co/1UiODwQiK6
Ultraprocessed Foods Increase Lupus Risk
  • MedPage Today
Among women followed for upwards of 25 years, those who ate relatively large amounts of "ultraprocessed" foods -- such as soft drinks, frozen pizzas, and mass-produced baked goods -- developed systemic lupus erythematosus at more than 50% greater rates than those with relatively low consumption, a new analysis of Nurses' Health Study data showed.
CHANCE-3 DBR-PCT of 8343 adults (>40yrs) w/ CVA or TIA & hsCRP ≥2 mg/L showed that colchicine (0.5mg) x 90d did

Dr. John Cush RheumNow

2 years 3 months ago
CHANCE-3 DBR-PCT of 8343 adults (>40yrs) w/ CVA or TIA & hsCRP ≥2 mg/L showed that colchicine (0.5mg) x 90d did not prevent (6.3% vs 6.5%; HR 0.98; 0.83 to 1.16) subsequent stroke within 90 days compared with placebo https://t.co/APiMYVkBTV https://t.co/VgFiCKfMqB
Paradoxical psoriasis w/ IL-17 inhib? Lit review 35 (SpA) pts, presenting as palmoplantar pustular and plaque PsO; media

Dr. John Cush RheumNow

2 years 3 months ago
Paradoxical psoriasis w/ IL-17 inhib? Lit review 35 (SpA) pts, presenting as palmoplantar pustular and plaque PsO; median 11 weeks after IL-17i. one-third continued IL-17i w/ mostly topical Rx; 2/3 D/C IL-17i, switching to other biologic w/ good outcomes https://t.co/q2xqQyiM3b https://t.co/6hSE6NLHWw
5 yr results of 150 difficult-to-treat RA pts - D2T RA resolved in 45%, persisted in 50%, & 5% died. Resolved D2T RA

Dr. John Cush RheumNow

2 years 3 months ago
5 yr results of 150 difficult-to-treat RA pts - D2T RA resolved in 45%, persisted in 50%, & 5% died. Resolved D2T RA was signif younger, had more Rx changes, & more IL-6i use. Mortality predicted by comorbidity index, steroid escalation (OR 3.50; & 32) https://t.co/cIUNcQ0r3F https://t.co/rNZaWu3Ocd
Cartesian Therapeutics, has announced their first-in-class mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) therapy has been given to the first systematic lupus erythematosus (SLE). patient in a Phase 2 open-label clinical trial. 
A retrospective cohort study of biological disease-modifying antirheumatic drugs (bDMARDs) persistence in rheumatoid arthritis (RA) patients with chronic kidney disease (CKD), shows the 3 year survicval to be under 50% but that all studied biologics were nearly equivalents with regard to safety and efficacy. 
In early arthritis (RA) pts there is no value in measuring for IgA-ACPA or IgA-RF, as there presence doesnt provide more

Dr. John Cush RheumNow

2 years 3 months ago
In early arthritis (RA) pts there is no value in measuring for IgA-ACPA or IgA-RF, as there presence doesnt provide more than IgG-ACPA. In tREACH trial IgA-ACPA present in 23% & overlaped w/ IgG-ACPA in 94% (w/ IgM-RF in 90%). https://t.co/d8Xc4GBfEt https://t.co/qvujVx0RFf
Does B Cell Depletion Matter?
CT angio in 75 pts w/ Takayasu arteritis (40 w/ cDMARDs, 35 biologics) showed reduced arterial thickness in 73% (31% w/

Dr. John Cush RheumNow

2 years 3 months ago
CT angio in 75 pts w/ Takayasu arteritis (40 w/ cDMARDs, 35 biologics) showed reduced arterial thickness in 73% (31% w/ >25% decr in wall thickness). 1st immunosuppressives (p= 0.012) & bDMARDs(p= 0.026) reduced art. wall thickness (relative to cDMARDs) https://t.co/16eGmgVoWr https://t.co/AyNyT7FsYZ
FDA adverse event study of JAKi in #RA assoc w/ signif more VTE, ischemic heart Dz, & tachyarrhythmias. 75,407 on JA

Dr. John Cush RheumNow

2 years 3 months ago
FDA adverse event study of JAKi in #RA assoc w/ signif more VTE, ischemic heart Dz, & tachyarrhythmias. 75,407 on JAKi vs 303,278 on biologics (TNFi, RTX, TCZ); JAK had more VTE (ROR=2.11), CVA (ROR=1.25), IHD (1.23), arrhythmias (1.15 ), esp in 1st yr. https://t.co/BmNPk6zN6o https://t.co/fbzHQmPmH5
Psoriatic Arthritis Topic Panel: EULAR 2024

Dr. Jack Cush moderates this topic panel with Drs. Eric Ruderman, Peter Nas

Dr. John Cush RheumNow

2 years 3 months ago
Psoriatic Arthritis Topic Panel: EULAR 2024 Dr. Jack Cush moderates this topic panel with Drs. Eric Ruderman, Peter Nash and Antoni Chan. https://t.co/XUFgUUqBu2 https://t.co/08TPtQWBvx
×